Spero therapeutics has acquired VXc 486 and VXc 100 with upfront payment and development mile stone payments. Spero has top notch ID guys on board. World need this drug. Drug works well in multidrug resistant tuberculosis by inhibiting gyrase B and also topoisomerase IV.
Enterome bio has open an office in Kindle Square and has acquired D-Mannose inhibitor patent license for EB 8018 as FmH antagonist for E. Coli.
JNJ should release plans for phase III of JNJ63623872 ( VX 787). JNJ had acquired Alios biopharma and thus Alios protease inhibitor for influenza and moving it as well in clinical trial.
Below is part of the news about Editas.
Editas, if successful, would be developing a method of fixing the actual gene responsible for the disease rather than a daily pill which counteracts that gene, like Vertex offers.
The author is very bullish with Regeneron. He thinks that it will reach 500 next year and has the annual growth rate of 35% beyond. $REGN composes 7% of IBB. It will lift IBB this week and Vertex has to follow IBB. Shorted shares will be toxic to your account. Cover them.
The results of phase 3 661 and phase 2 787 for influenza should become available in may 2016. I wonder when they will make an announcement of the results.
Also phase 1 results for 970 should be available this September.
EU CF meeting next month should give insight into efficacy of VX 661/770 as Phase 3 studies from VRTX are reported at this meeting. It may soon replace lumacaftor in 508dd cf with better results.as well as become standard treatment of gating mutations with a 508 allele if it demonstrates incremental benefit over kalydeco treatment alone. It will open the door for Vertex to treat the 508d heterozygote'het min'CF population with a second corrector,
A triple combo has been the end game for years. It's interesting that they're far enough along on potentiators and correctors to just go for it. Like, if it fails, what if they had a great corrector but a lousy potentiator for some reason? Or what if they had a great potentiator and first corrector but a lousy second corrector? In any event, Vertex is also working on a triple combo and I hope this motivates them to work faster. Oh, and both my kids are still taking Orkambi for what it's worth.
AbbVie ($ABBV) has expanded its cystic fibrosis deal with Galapagos ($GLPG), positioning the Belgian biotech to pocket $250 million (#$%$218 million) more than under the original agreement if it hits all of its milestones. The dialed-up deal follows a shift in focus from double to triple combinations of cystic fibrosis drugs, an evolution that has increased the early-phase workload Galapagos is shouldering.
Galapagos is aiming to start testing its triple combination in humans next year.
"BRIEF-Vertex Pharmaceuticals files for potential mixed shelf
— 5:48 PM ET 05/03/2016
May 3 (Reuters) - Vertex Pharmaceuticals Inc
* Files for potential mixed shelf; size not disclosed - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)"
Apparently investors do not think that is a positive development.
I no longer own VRTX but am looking to add at the right price. I went through about 10 videos and they all positive except for 2 (same person) that were neutral since Orkambi did not work for her. It seems even for this patient the side effects went away. Everyone else seemed very positive. So your whole rationale is BS.
He is in the top 10 highest paid. Tell that to congress when he testifies on the exorbitant drug pricing of between $250,000 and $330,000 per patient.
CF patients will try anything but the side effects of Orkambi are horrible. Go to You Tube for personal experiences. The drug is also enormously expensive so Vertex is trying to force patients to stick with it.
they digested what management says and we get better ideas where things stand now and going forward...they like what they read and saw...they see the stock being cheap down here...110 by end of year is what wall street expects...vrtx owns the cf market.